Related Experiment Video
Updated: Oct 12, 2025
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Urocortin Role in Ischemia Cardioprotection and the Adverse Cardiac Remodeling
Eva M Calderón-Sánchez1, Débora Falcón1,2, Marta Martín-Bórnez1,2
1Group of Cardiovascular Pathophysiology, Institute of Biomedicine of Seville, University Hospital of Virgen del Rocío/University of Seville/CSIC, 41013 Seville, Spain.
Insights
Urocortin (Ucn) isoforms show promise in protecting the heart from ischemia and reperfusion injury. These stress-associated peptides may offer new cardioprotective therapies for heart failure and ischemic heart disease.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Pharmacology
Background:
- Ischemic heart diseases (IHD) and heart failure (HF) are leading global causes of mortality.
- Myocardial protection strategies are advancing, yet ischemia and reperfusion (I/R) injury remains a significant challenge.
- I/R syndrome causes further damage post-revascularization, leading to adverse cardiac remodeling and HF progression.
Purpose of the Study:
- To review the current knowledge on urocortin (Ucn) isoforms in cardioprotection.
- To highlight the potential of Ucn isoforms as novel therapeutic agents for IHD and HF.
- To focus on the acute and long-term effects of Ucn isoforms on cardiovascular function.
Main Methods:
- Review of existing animal studies and pilot clinical trials.
- Analysis of signaling pathways targeted by Ucn isoforms.
- Examination of molecular mechanisms underlying Ucn-mediated cardioprotection.
Main Results:
- Urocortin isoforms demonstrate potential in improving cardiovascular functions.
- Evidence suggests Ucn isoforms target multiple signaling pathways at various molecular levels.
- Pilot studies indicate promising effects in HF patients.
Conclusions:
- Urocortin isoforms represent a promising therapeutic avenue for cardioprotection against I/R injury.
- Further research into Ucn isoforms could lead to effective treatments for IHD and HF.
- Targeting Ucn pathways offers a novel strategy to combat heart disease progression.
Abstract:
Despite the considerable progress in strategies of myocardial protection, ischemic heart diseases (IHD) and consequent heart failure (HF) remain the main cause of mortality worldwide. Several procedures are used routinely to guarantee the prompt and successful reestablishment of blood flow to preserve the myocardial viability of infarcted hearts from ischemia injuries. However, ischemic heart reperfusion/revascularization triggers additional damages that occur when oxygen-rich blood re-enters the vulnerable myocardial tissue, which is a phenomenon known as ischemia and reperfusion (I/R) syndrome. Complications of I/R injuries provoke the adverse cardiac remodeling, involving inflammation, mishandling of Ca2+ homeostasis, apoptotic genes activation, cardiac myocytes loss, etc., which often progress toward HF. Therefore, there is an urgent need to develop new cardioprotective therapies for IHD and HF. Compelling evidence from animal studies and pilot clinical trials in HF patients suggest that urocortin (Ucn) isoforms, which are peptides associated with stress and belonging to the corticotropin releasing factor family, have promising potential to improve cardiovascular functions by targeting many signaling pathways at different molecular levels. This review highlights the current knowledge on the role of urocortin isoforms in cardioprotection, focusing on its acute and long-term effects.
